Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Although Immunex Corp. shares dropped $9.31 last Monday in the wake of the New Year's Eve approval of G.D.Searle & Co.'s Celebrex celecoxib, IMNX believes its Enbrel etanercept soluble TNF
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury